Document Detail


Ebselen abrogates TNFalpha induced pro-inflammatory response in glioblastoma.
MedLine Citation:
PMID:  19383369     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We investigated the pro-inflammatory response mediated by TNFalpha in glioblastoma and whether treatment with organoselenium Ebselen (2-phenyl-1,2-benzisoselenazol-3[2H]one) can affect TNFalpha induced inflammatory response. Exposure to TNFalpha increased the expression of pro-inflammatory mediator interleukin IL-6, IL-8, monocyte chemoattractant protein-1 (MCP-1) and cyclooxygenase (COX-2). Treatment with Ebselen abrogated TNFalpha induced increase in pro-inflammatory mediators. Ebselen not only abrogated TNFalpha induced enhanced invasiveness of glioma cells by down-regulating matrix metallo proteinase (MMP-9) and urokinase plasminogen (uPa) activity, but also inhibited glioma cell migration. Treatment with Ebselen also down-regulated the enhanced ROS production of TNFalpha treated glioma cells. In addition, Ebselen induced DNA damage repair signaling response in glioma cells both in the presence and absence of TNFalpha. These studies indicate that together with its known ability to sensitize glioma cell to TNFalpha induced apoptosis, Ebselen can overcome TNFalpha induced pro-inflammatory mediators to prevent a build up of a deleterious pro-inflammatory tumor microenvironment.
Authors:
Richa Tewari; Vivek Sharma; Nitin Koul; Abhishek Ghosh; Christy Joseph; Ugir Hossain Sk; Ellora Sen
Related Documents :
22726809 - Within-host dynamics of mycoplasma infections: conjunctivitis in wild passerine birds.
22246599 - Anti-inflammatory properties and pharmacological induction of hsp70 after brain injury.
22846899 - E-ntpdase and e-ada activities are altered in lymphocytes of patients with indeterminat...
19617629 - Adiponectin inhibits pro-inflammatory signaling in human macrophages independent of int...
20425759 - Systemic inflammatory load in humans is suppressed by consumption of two formulations o...
12464149 - Traditional therapies: glucocorticoids, azathioprine, methotrexate, hydroxyurea.
17590379 - Distal tubular epithelial cells of the kidney: potential support for proximal tubular c...
17169139 - Bench-to-bedside review: the role of activated protein c in maintaining endothelial tig...
6804159 - Mechanisms of lung injury.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2008-11-05
Journal Detail:
Title:  Molecular oncology     Volume:  3     ISSN:  1878-0261     ISO Abbreviation:  Mol Oncol     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-04-22     Completed Date:  2009-07-20     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101308230     Medline TA:  Mol Oncol     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  77-83     Citation Subset:  IM    
Affiliation:
National Brain Research Centre, Manesar, Gurgaon, Haryana 122 050, India.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Azoles / pharmacology*,  therapeutic use
Cell Movement / drug effects
DNA Repair
Gene Expression Regulation / drug effects
Glioblastoma / pathology*
Humans
Inflammation / chemically induced,  drug therapy*
Inflammation Mediators / analysis
Organoselenium Compounds / pharmacology*,  therapeutic use
Tumor Necrosis Factor-alpha / pharmacology*
Chemical
Reg. No./Substance:
0/Azoles; 0/Inflammation Mediators; 0/Organoselenium Compounds; 0/Tumor Necrosis Factor-alpha; 60940-34-3/ebselen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  HBx genotype D represses GSTP1 expression and increases the oxidative level and apoptosis in HepG2 c...
Next Document:  The Bayh-Dole Act: a model for promoting research translation?